title: Alpha-noradrenergic receptor modulation of the phencyclidine- and delta9-tetrahydrocannabinol-induced increases in dopamine utilization in rat prefrontal cortex.
abstract: The noncompetitive NMDA receptor antagonist phencyclidine (PCP) and the neuronal cannabinoid receptor agonist delta9-tetrahydrocannabinol (THC) are two agents shown to have psychotomimetic properties in humans. Both drugs increase dopamine release and utilization in the prefrontal cortex, a brain region thought to be dysfunctional in schizophrenia. In the present series of studies, the effects of drugs acting at alpha-noradrenergic receptors on PCP- and THC-induced increases in prefrontal cortical and nucleus accumbens dopamine utilization in the rat were examined. Clonidine, an alpha2 noradrenergic receptor agonist, completely blocked the activation of mesoprefrontal dopamine system by THC or PCP. In addition, the alpha1 noradrenergic receptor antagonist prazosin blocked the PCP-induced increase in prefrontal cortical dopamine utilization. These data may provide new insights concerning pharmacological therapies for acute drug-induced psychoses and behavioral abnormalities in human PCP and THC abusers.
authors.affiliation: Neuropsychopharmacology Research Unit, Yale University School of Medicine, New Haven, Connecticut 06520-8066, USA.
authors.forename: J D
authors.initials: JD
authors.lastname: Jentsch
authors.forename: A
authors.initials: A
authors.lastname: Wise
authors.forename: Z
authors.initials: Z
authors.lastname: Katz
authors.forename: R H
authors.initials: RH
authors.lastname: Roth
mesh_terms: D000316:Adrenergic alpha-Agonists / Q000494:pharmacology; D000317:Adrenergic alpha-Antagonists / Q000378:metabolism / Q000494:pharmacology*; D000818:Animals; D003000:Clonidine / Q000494:pharmacology; D004298:Dopamine / Q000378:metabolism*; D018765:Dopamine Uptake Inhibitors / Q000494:pharmacology; D013759:Dronabinol / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D016316:Guanfacine / Q000494:pharmacology; D006213:Hallucinogens / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D008297:Male; D009714:Nucleus Accumbens / Q000187:drug effects / Q000378:metabolism; D010622:Phencyclidine / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D011224:Prazosin / Q000494:pharmacology; D017397:Prefrontal Cortex / Q000187:drug effects* / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D011942:Receptors, Adrenergic, alpha / Q000187:drug effects* / Q000378:metabolism
chemical_list: D000316:Adrenergic alpha-Agonists; D000317:Adrenergic alpha-Antagonists; D018765:Dopamine Uptake Inhibitors; D006213:Hallucinogens; D011942:Receptors, Adrenergic, alpha; D016316:Guanfacine; D013759:Dronabinol; D010622:Phencyclidine; D003000:Clonidine; D004298:Dopamine; D011224:Prazosin